Showing posts with label IBD. Show all posts
Showing posts with label IBD. Show all posts

Saturday, January 02, 2016

IBD Top 50 Stocks Strategy – 2015 Final!

Here is the IBD 50 stocks investing strategies vs. $SPY. We have a winner!  Buying and reallocating weekly to the IBD top 10 stocks outperfomed this last year.  This analysis is from 1/1/2015 through  12/31/2015.
I didn’t track and blog about these weekly or monthly in 2015, as my overall blogging activity fell off a cliff!  These stocks tend to be high beta, and at times the portfolio was significantly ahead of the index, only to underperform like crazy on any market pullback.  It seems like high beta gets punished the most when the market mood sours. 

image 2015 is over, and the SP500 underperformed most of the IBD 50 investing strategies.   The opposite of 2014.
The portfolio is sold at the closing price Friday night, and rebalanced into the make-up of the IBD top 50.  Dividends are excluded from total returns.
image The IBD monthly strategy also outperformed  the SP500 in most cases.  Holding and rebalancing each month into just the top 5 IBD stocks came out on top.
The more diversified portfolios were closer to the return of the SP500.
I will assume a $9.95 trading cost to sell last week’s or last month’s portfolio, and $9.95 to buy the new weekly or monthly portfolio.  (Imagine the costs of doing this with individual stocks, compared to using Motif.  Note that Motif limits the size of portfolios to 30 stocks).
The Top 25 holdings are listed at at Motif Investing.
None of the above strategies are a recommendation to buy or sell stocks.  These are model portfolios constructed for entertainment only.
Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model.  Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month.  It is assumed that trading costs are $9.95 to “buy” a model portfolio, and $9.95 to “sell” a model portfolio.  Thus, each weekly or monthly rebalance out of the previous portfolio and into the new portfolio costs $19.90.  Daily changes in the IBD 50 or stock rankings are not considered.  Changes in IBD’s overall market views are not considered.  Stop loss orders or other market timing strategies are not considered.  The value for SPY is based on buying at the closing price the last trading day of the preceding year.
Based on a blog entry from Paladin Money.  See Investors Business Daily for more information on the IBD 50.  See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks.

Sunday, November 23, 2014

IBD Top 50 Stocks Strategy – 11/23/2014

Here is the latest on the IBD 50 stocks investing strategies vs. $SPY

image  Since the last update near the October lows, the market has raced ahead of the IBD 50 stocks.   For the week, there were 25 stocks up and 25 stocks down for the IBD 50.

VRX led the IBD 50, up 8.32% for the week.  The biggest loser for the IBD 50 was VIPS, down 7.32%.

The IBD 50 portfolios total return since 2/8/2014 are underperforming the SP500.  None of the strategies are beating the simple SP500 at this point. I would have expected to see the leading stocks lead, but there has been more volatility in some of the top stocks as measured by IBD.

The portfolio is sold at the closing price Friday night, and rebalanced into the make-up of the IBD top 50.  Dividends are excluded from total returns.

Trading costs $805.95.

image The IBD monthly strategy is also underperforming  the SP500.

All of the portfolios have a positive return for the month, but have a positive total return. 

The IBD 50 has 28 gainers and 22 losers in November.

AFSI is the top performer for the IBD 50, returning 13.91%.  The weakest stock in the IBD 50 so far is SLXP, losing 28.47%.

Trading costs $169.15

I will assume a $9.95 trading cost to sell last week’s or last month’s portfolio, and $9.95 to buy the new weekly or monthly portfolio.  (Imagine the costs of doing this with individual stocks, compared to using Motif.  Note that Motif limits the size of portfolios to 30 stocks).

The Top 25 holdings are listed at at Motif Investing.  (A check as of 3/31/2014 shows that the ability to view all holdings is limited to Motif members and IBD subscribers).

None of the above strategies are a recommendation to buy or sell stocks.  These are model portfolios constructed for entertainment only.

This is the IBD portfolio performance since 2/8/2014.  Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model.  Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month.  It is assumed that trading costs are $9.95 to “buy” a model portfolio, and $9.95 to “sell” a model portfolio.  Thus, each weekly or monthly rebalance out of the previous portfolio and into the new portfolio costs $19.90.  Daily changes in the IBD 50 or stock rankings are not considered.  Changes in IBD’s overall market views are not considered.  Stop loss orders or other market timing strategies are not considered.  The value for SPY is based on buying 2/8/2014.

Based on a blog entry from Paladin Money.  See Investors Business Daily for more information on the IBD 50.  See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks.

Sunday, October 19, 2014

IBD Top 50 Stocks Strategy – 10/19/2014

Here is the latest on the IBD 50 stocks investing strategies vs. $SPY

imageDespite the crazy hair-pulling volatility, the IBD 50 portfolios outperformed the broad index this week.   For the week, there were 32 stocks up and 18 stocks down for the IBD 50.

ATHM led the IBD 50, up 18.19% for the week.  The biggest loser for the IBD 50 was LAD, down 12.84%.

The IBD 50 portfolios total return since 2/8/2014 are underperforming the SP500. For anyone expecting a bounce or a rally into the end of the year, what outperforms from here?  Will the strategies continue to lead the way in the direction the market is heading?

The portfolio is sold at the closing price Friday night, and rebalanced into the make-up of the IBD top 50.  Dividends are excluded from total returns.

Trading costs $706.45.

image The IBD monthly strategy is mixed versus  the SP500.

The portfolios concentrated in fewer holdings are performing better than the more diversified portfolios. Only the IBD 5 has a positive return at this time.

The IBD 50 has 7 gainers and 43 losers. 

ATHM is the top performer for the IBD 50, returning 12.31%.  The weakest stock in the IBD 50 so far is SLCA, losing 24.28%.

Trading costs $149.25

I will assume a $9.95 trading cost to sell last week’s or last month’s portfolio, and $9.95 to buy the new weekly or monthly portfolio.  (Imagine the costs of doing this with individual stocks, compared to using Motif.  Note that Motif limits the size of portfolios to 30 stocks).

The Top 25 holdings are listed at at Motif Investing.  (A check as of 3/31/2014 shows that the ability to view all holdings is limited to Motif members and IBD subscribers).

None of the above strategies are a recommendation to buy or sell stocks.  These are model portfolios constructed for entertainment only.

This is the IBD portfolio performance since 2/8/2014.  Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model.  Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month.  It is assumed that trading costs are $9.95 to “buy” a model portfolio, and $9.95 to “sell” a model portfolio.  Thus, each weekly or monthly rebalance out of the previous portfolio and into the new portfolio costs $19.90.  Daily changes in the IBD 50 or stock rankings are not considered.  Changes in IBD’s overall market views are not considered.  Stop loss orders or other market timing strategies are not considered.  The value for SPY is based on buying 2/8/2014.

Based on a blog entry from Paladin Money.  See Investors Business Daily for more information on the IBD 50.  See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks.

Saturday, October 11, 2014

Update – The IBD Top 50 Stocks Strategy

Here is the latest on the IBD 50 stocks investing strategies vs. $SPY

Another bad week for the IBD 50 portfolios.  Yuck!  image When the stock market is in an uptrend, the IBD 50 portfolios outperform.  When the stock market is heading south, the IBD 50 portfolios do much worse.  There is no surprise what happened here this week.  For the week, there were 0 stocks up and 50 stocks down for the IBD 50. 

XRS led the IBD 50, declining 1.17 for the week.  The biggest loser for the IBD 50 was EMES, down 21.89%.

The IBD 50 portfolios total return since 2/8/2014 are now underperforming the SP500. For anyone expecting a bounce or a rally into the end of the year, what outperforms from here?

The portfolio is sold at the closing price Friday night, and rebalanced into the make-up of the IBD top 50.  Dividends are excluded from total returns.

Trading costs $686.55.

image The IBD monthly strategy is underperforming  the SP500.

The portfolios concentrated in fewer holdings are performing better than the more diversified portfolios. Only the IBD 5 has a positive return at this time.

The IBD 50 has 2 gainers and 48 losers. 

AAP was the top performer for the IBD 50, returning 1.93%.  The weakest stock in the IBD 50 so far is SLCA, losing 27.02%.

Trading costs $149.25

I will assume a $9.95 trading cost to sell last week’s or last month’s portfolio, and $9.95 to buy the new weekly or monthly portfolio.  (Imagine the costs of doing this with individual stocks, compared to using Motif.  Note that Motif limits the size of portfolios to 30 stocks).

The Top 25 holdings are listed at at Motif Investing.  (A check as of 3/31/2014 shows that the ability to view all holdings is limited to Motif members and IBD subscribers).

None of the above strategies are a recommendation to buy or sell stocks.  These are model portfolios constructed for entertainment only.

This is the IBD portfolio performance since 2/8/2014.  Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model.  Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month.  It is assumed that trading costs are $9.95 to “buy” a model portfolio, and $9.95 to “sell” a model portfolio.  Thus, each weekly or monthly rebalance out of the previous portfolio and into the new portfolio costs $19.90.  Daily changes in the IBD 50 or stock rankings are not considered.  Changes in IBD’s overall market views are not considered.  Stop loss orders or other market timing strategies are not considered.  The value for SPY is based on buying 2/8/2014.

Based on a blog entry from Paladin Money.  See Investors Business Daily for more information on the IBD 50.  See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks.

Sunday, October 05, 2014

Update – The IBD Top 50 Stocks Strategy

Here is the latest on the IBD 50 stocks investing strategies vs. $SPY

imageI’ve been tracking the IBD 50 stocks since February.  When the stock market is in an uptrend, the IBD 50 portfolios outperform.  When the stock market is heading south, the IBD 50 portfolios do much worse.  This past week was a prime example of the latter.  If the stock market reversed at the end of the week and is heading higher, then guess what’s going to happen to the IBD 50 stocks?  Zoom!  For the week, there were 20 stocks up and 30 stocks down for the IBD 50. 

ALXN led the IBD 50 with a return of 6.16% for the week.  The biggest loser for the IBD 50 was SLCA, down 14.31%.

The IBD 50 portfolios total return since 2/8/2014 are mixed versus the SP500. The portfolios containing a higher number of stocks tends to perform closer to the SP500, while the portfolios concentrated in fewer stocks tend to be more volatile! 

The portfolio is sold at the closing price Friday night, and rebalanced into the make-up of the IBD top 50.  Dividends are excluded from total returns.

Trading costs $666.65.

image The IBD monthly strategy is a mixed bag compared to the SP500.

The portfolios concentrated in fewer holdings are performing better than the more diversified portfolios. Only the IBD 5 is outperforming the SPY at this time.

For the first few days of October, the IBD 50 has 21 gainers and 29 losers.  The portfolios with more holdings are holding closer to the SP500, while the concentration in fewer high-flyers have taken more of a hit.  But the latter has also outperformed since I started tracking the strategies.

ALXN was the top performer for the IBD 50, returning 7.33%.  The weakest stock in the IBD 50 so far is SLCA, losing 13.04%.

Trading costs $149.25

As I have been reading reviews of investing and rebalancing into model portfolios, the trading costs of rebalancing weekly or monthly is often discussed.  Going forward, I will list the “in and out” rebalancing costs for each strategy.  I will assume a $9.95 cost to sell last week’s or last month’s portfolio, and $9.95 to buy the new weekly or monthly portfolio.  (Imagine the costs of doing this with individual stocks, compared to using Motif.  Note that Motif limits the size of portfolios to 30 stocks).

The Top 25 holdings are listed at at Motif Investing.  (A check as of 3/31/2014 shows that the ability to view all holdings is limited to Motif members and IBD subscribers).

None of the above strategies are a recommendation to buy or sell stocks.  These are model portfolios constructed for entertainment only.

This is the IBD portfolio performance since 2/8/2014.  Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model.  Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month.  It is assumed that trading costs are $9.95 to “buy” a model portfolio, and $9.95 to “sell” a model portfolio.  Thus, each weekly or monthly rebalance out of the previous portfolio and into the new portfolio costs $19.90.  Daily changes in the IBD 50 or stock rankings are not considered.  Changes in IBD’s overall market views are not considered.  Stop loss orders or other market timing strategies are not considered. 

Based on a blog entry from Paladin Money.  See Investors Business Daily for more information on the IBD 50.  See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks.

Monday, September 15, 2014

Growth Stocks Hammered

Not a good day for growth stocks. Check out the IBD50!  Wow!

Saturday, September 06, 2014

Update – The IBD Top 50 Stocks Strategy

Here is the latest on the IBD 50 stocks investing strategies vs. $SPY

imageSince I last updated the strategy, the market has been on an amazing run and the popular, high beta stocks have been outperforming.  As the portfolios reallocate each Friday night to the latest IBD updates, all of the portfolios are outperforming the SPY.  For the week, there were 28 stocks up and 22 stocks down for the IBD 50. 

AMBA led the IBD 50 with a return of 7.74% for the week.  The biggest loser for the IBD 50 was FANG, down 8.22%.

The total return since 2/8/2014 is outperforming the SP500. As the market rallies, the portfolios concentrated in fewer high-flying positions are outperforming the portfolios that are more diversified with more positions. 

The portfolio is sold at the closing price Friday night, and rebalanced into the make-up of the IBD top 50.  Dividends are excluded from total returns.

Trading costs $567.15.

image The IBD monthly strategy has also had an amazing run for the year, after looking a little wobbly after each small pullback.

The portfolios concentrated in fewer holdings are outperforming the market as a whole.  Only the IBD 50 is underperforming the SPY at this time.

image Since September is just getting started, lets take a quick look back on August to see how the strategy performed compared to the SP500.

For the month of August, the IBD 50 has 44 gainers and 6 losers.  Each portfolio smoked the returns of the market.  And the more concentrated the portfolio in fewer stocks, the better the return.

BITA was the top performer for the IBD 50, returning 61.57%.  It was also in each of the portfolios, so the more concentrated holding benefitted each portfolio dramatically.  For example, if you own only 5 stocks and one of them is up 61%, it’s likely you’re looking at your account statement and wearing a watermelon smile.  The weakest stock in the IBD 50 for August was ARRS, losing 10.42%.

Trading costs $109.45

As I have been reading reviews of investing and rebalancing into model portfolios, the trading costs of rebalancing weekly or monthly is often discussed.  Going forward, I will list the “in and out” rebalancing costs for each strategy.  I will assume a $9.95 cost to sell last week’s or last month’s portfolio, and $9.95 to buy the new weekly or monthly portfolio.  (Imagine the costs of doing this with individual stocks, compared to using Motif.  Note that Motif limits the size of portfolios to 30 stocks).

The Top 25 holdings are listed at at Motif Investing.  (A check as of 3/31/2014 shows that the ability to view all holdings is limited to Motif members and IBD subscribers).

None of the above strategies are a recommendation to buy or sell stocks.  These are model portfolios constructed for entertainment only.

This is the IBD portfolio performance since 2/8/2014.  Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model.  Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month.  It is assumed that trading costs are $9.95 to “buy” a model portfolio, and $9.95 to “sell” a model portfolio.  Thus, each weekly or monthly rebalance out of the previous portfolio and into the new portfolio costs $19.90.  Daily changes in the IBD 50 or stock rankings are not considered.  Changes in IBD’s overall market views are not considered.  Stop loss orders or other market timing strategies are not considered. 

Based on a blog entry from Paladin Money.  See Investors Business Daily for more information on the IBD 50.  See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks.

Thursday, July 31, 2014

Update – The IBD Top 50 Stocks Strategy

Here is the latest on the IBD 50 stocks investing strategies vs. $SPY (only monthly model today).

image The IBD monthly strategy continues to lag the SP500 as July comes to a close. 

The total returns for all monthly models continue to trail the SP500.  It probably isn’t a shocker that trying to pick just the winning stocks lags a more diversified index.  Especially since the winning stocks are often added to the IBD 50 list after a huge move is already in a stock.  The idea is that stocks that have gone up will continue to go up.  Hmm.

BITA led the monthly IBD 50 models with an 11.6% return.  On the downside, AFOP fell 26.1%.

For the month of July, the IBD 50 had 17 gainers and 33 losers. 

Trading costs $89.65.

As I have been reading reviews of investing and rebalancing into model portfolios, the trading costs of rebalancing weekly or monthly is often discussed.  Going forward, I will list the “in and out” rebalancing costs for each strategy.  I will assume a $9.95 cost to sell last week’s or last month’s portfolio, and $9.95 to buy the new weekly or monthly portfolio.  (Imagine the costs of doing this with individual stocks, compared to using Motif.  Note that Motif limits the size of portfolios to 30 stocks).

The Top 25 holdings are listed at at Motif Investing.  (A check as of 3/31/2014 shows that the ability to view all holdings is limited to Motif members and IBD subscribers).

None of the above strategies are a recommendation to buy or sell stocks.  These are model portfolios constructed for entertainment only.

This is the IBD portfolio performance since 2/8/2014.  Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model.  Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month.  It is assumed that trading costs are $9.95 to “buy” a model portfolio, and $9.95 to “sell” a model portfolio.  Thus, each weekly or monthly rebalance out of the previous portfolio and into the new portfolio costs $19.90.  Daily changes in the IBD 50 or stock rankings are not considered.  Changes in IBD’s overall market views are not considered.  Stop loss orders or other market timing strategies are not considered. 

Based on a blog entry from Paladin Money.  See Investors Business Daily for more information on the IBD 50.  See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks.

Sunday, June 15, 2014

Update – The IBD Top 50 Stocks Strategy

Here is the latest on the IBD 50 stocks investing strategies vs. $SPY

imageThis last week was a mixed performance for the IBD 50 models.  The market struggled with the violence in Iraq and the Eric Cantor defeat (so they say).  For the week, there were 18 stocks up and 32 stocks down for the IBD 50. 

UBNT led the IBD 50 with a return of 13.8% for the week.  The biggest loser for the IBD 50 was AL down 10.6%.

The total return since 2/8/2014 is underperforming the SP500.  While none of the IBD 50 models are outperforming the SP500, the more diversified model (with 50 stocks) is performing better than the less-diversified models. 

The portfolio is sold at the closing price Friday night, and rebalanced into the make-up of the IBD top 50.  Dividends are excluded from total returns.

Trading costs $348.25.

image The IBD monthly strategy is also lagging the SP500 for the month of June. 

The total returns for all monthly models continue to trail the SP500.  Fear in the Middle East may hamper growth stocks for the time being.

FANG leads the monthly IBD 50 models with a 16.5% return.  On the downside, VRX has fallen 8.85%.

For the month of June, the IBD 50 has 28 gainers and 22 losers. 

 

Trading costs $69.65.

As I have been reading reviews of investing and rebalancing into model portfolios, the trading costs of rebalancing weekly or monthly is often discussed.  Going forward, I will list the “in and out” rebalancing costs for each strategy.  I will assume a $9.95 cost to sell last week’s or last month’s portfolio, and $9.95 to buy the new weekly or monthly portfolio.  (Imagine the costs of doing this with individual stocks, compared to using Motif.  Note that Motif limits the size of portfolios to 30 stocks).

The Top 25 holdings are listed at at Motif Investing.  (A check as of 3/31/2014 shows that the ability to view all holdings is limited to Motif members and IBD subscribers).

None of the above strategies are a recommendation to buy or sell stocks.  These are model portfolios constructed for entertainment only.

This is the IBD portfolio performance since 2/8/2014.  Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model.  Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month.  It is assumed that trading costs are $9.95 to “buy” a model portfolio, and $9.95 to “sell” a model portfolio.  Thus, each weekly or monthly rebalance out of the previous portfolio and into the new portfolio costs $19.90.  Daily changes in the IBD 50 or stock rankings are not considered.  Changes in IBD’s overall market views are not considered.  Stop loss orders or other market timing strategies are not considered. 

Based on a blog entry from Paladin Money.  See Investors Business Daily for more information on the IBD 50.  See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks.

Monday, May 26, 2014

Update – The IBD Top 50 Stocks Strategy

Here is the latest on the IBD 50 stocks investing strategies vs. $SPY

imageAha! Another good week for the IBD 50 that reminds us why growth stocks are so popular while the market is advancing.  All of the IBD weekly strategies ending 5/23/2014 outperformed the SP500.  For the week, there were 41 stocks up and 9 stocks down for the IBD 50. 

AFOP led the IBD 50 with a return of 13.7% for the week.  The biggest loser for the IBD 50 was MYGN down 10.3%.

The total return since 2/8/2014 is underperforming the SP500.  While none of the IBD 50 models are outperforming the SP500, the more diversified model (with 50 stocks) is performing better than the less-diversified models. 

The portfolio is sold at the closing price Friday night, and rebalanced into the make-up of the IBD top 50.  Dividends are excluded from total returns.

Trading costs $288.55.

image The IBD monthly strategy has edged into the green for the month of May, just as the overall market makes all time highs.

The total returns for the monthly models continue to trail the SP500.  The growth stocks are making a strong move as the month winds down.

GMCR leads the monthly IBD 50 models with a 21.7% return.  On the downside, MYGN has fallen 21.3%.

For the month of May, the IBD 50 has 34 gainers and 16 losers. 

The upcoming week will conclude the month of May, and the models will rebalance into the latest top IBD 50 stocks.

Trading costs $29.85.

As I have been reading reviews of investing and rebalancing into model portfolios, the trading costs of rebalancing weekly or monthly is often discussed.  Going forward, I will list the “in and out” rebalancing costs for each strategy.  I will assume a $9.95 cost to sell last week’s or last month’s portfolio, and $9.95 to buy the new weekly or monthly portfolio.  (Imagine the costs of doing this with individual stocks, compared to using Motif.  Note that Motif limits the size of portfolios to 30 stocks).

The Top 25 holdings are listed at at Motif Investing.  (A check as of 3/31/2014 shows that the ability to view all holdings is limited to Motif members and IBD subscribers).

None of the above strategies are a recommendation to buy or sell stocks.  These are model portfolios constructed for entertainment only.

This is the IBD portfolio performance since 2/8/2014.  Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model.  Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month.  It is assumed that trading costs are $9.95 to “buy” a model portfolio, and $9.95 to “sell” a model portfolio.  Thus, each weekly or monthly rebalance out of the previous portfolio and into the new portfolio costs $19.90.  Daily changes in the IBD 50 or stock rankings are not considered.  Changes in IBD’s overall market views are not considered.  Stop loss orders or other market timing strategies are not considered. 

Based on a blog entry from Paladin Money.  See Investors Business Daily for more information on the IBD 50.  See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks.

Saturday, May 10, 2014

Update – The IBD Top 50 Stocks Strategy

Here’s a late update on the IBD Top 50 stocks investing strategies vs. $SPY

image The IBD weekly strategy ending 5/9/2014 underperformed the SP500 – by quite a bit.  For the week, there were 41 stocks down and 9 stocks up for the IBD 50. 

GMCR led the IBD 50 with a return of over 19% for the week.  The biggest loser for the IBD 50 was UBNT, down over 23%.  UBNT reported earnings and the stock sold off hard.  Only one stock in the IBD 5 was positive for the week!

The total return since 2/8/2014 is underperforming the SP500.  None of the IBD models has a positive return for 2014.  The more diversified model (with 50 stocks) is performing better than the less-diversified models.  The market index is near an all time high, but the growth stocks have been sold off in favor of the larger cap Dow names.  (This is not usually a good sign, by the way).

The portfolio is sold at the closing price Friday night, and rebalanced into the make-up of the IBD top 50.  Dividends are excluded from total returns.

Trading costs $248.75.

image The IBD monthly strategy kicked off a new month hovering near the returns of the SP500.  The IBD 5 was the only model to have a positive return, while the more diversified IBD 50 came in last. 

The total returns for the monthly models are struggling to match the SP500, and are trailing by quite a bit.  While it may seem as if all hope is lost, the models consist of growth stocks.  If growth stocks ever see cash inflow again, these stocks could once again take the lead.

That’s not happening now!

With just over a week of trading in the books, the IBD 50 has 14 gainers and 36 losers. 

Trading costs $29.85.

As I have been reading reviews of investing and rebalancing into model portfolios, the trading costs of rebalancing weekly or monthly is often discussed.  Going forward, I will list the “in and out” rebalancing costs for each strategy.  I will assume a $9.95 cost to sell last week’s or last month’s portfolio, and $9.95 to buy the new weekly or monthly portfolio.  (Imagine the costs of doing this with individual stocks, compared to using Motif.  Note that Motif limits the size of portfolios to 30 stocks).

The Top 25 holdings are listed at at Motif Investing.  (A check as of 3/31/2014 shows that the ability to view all holdings is limited to Motif members and IBD subscribers).

None of the above strategies are a recommendation to buy or sell stocks.  These are model portfolios constructed for entertainment only.

This is the IBD portfolio performance since 2/8/2014.  Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model.  Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month.  It is assumed that trading costs are $9.95 to “buy” a model portfolio, and $9.95 to “sell” a model portfolio.  Thus, each weekly or monthly rebalance out of the previous portfolio and into the new portfolio costs $19.90.  Daily changes in the IBD 50 or stock rankings are not considered.  Changes in IBD’s overall market views are not considered.  Stop loss orders or other market timing strategies are not considered. 

Based on a blog entry from Paladin Money.  See Investors Business Daily for more information on the IBD 50.  See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks.

Tuesday, April 22, 2014

IBD 50 Model Portfolio Update

IBD 50 model portfolio update: Oops. Been dealing with computer virus and then Easter. The next thing you know, the week got away from me.

Back next weekend.  With the SP500 up 6 days in a row, we could see quite a comeback for the IBD strategies!  Stay tuned!

Sunday, April 06, 2014

Update – The IBD Top 50 Stocks Strategy

Here’s a late update on the IBD Top 50 stocks investing strategies vs. $SPY

imageThe IBD weekly strategy ending 4/4/2014 had another bad week.  While the SP500 remains near all time highs, the more volatile stocks that make up the Nasdaq and the IBD 50 are getting hit with institutional selling.

The market has been seeing rotation out of the high beta and volatile names into the big cap value names.  Many large institutional investors have to be invested 100% of the time, and when the high beta names stop working, money flows into the names that are more highly liquid and that pay dividends.  These big cap stocks are often seen as “safe,” although they eventually get sold off should the market go into a bigger correction. 

For the week, there were 22 stocks up and 28 stocks down for the IBD 50.  Only 1 of 4 in the top IBD 5 stocks was positive for the week.

The total return since 2/8/2014 is underperforming the SP500.  None of the IBD models has a positive return for 2014.

The portfolio is sold at the closing price Friday night, and rebalanced into the make-up of the IBD top 50.

image The IBD monthly strategy has had a rough April so far.  What’s interesting is that the portfolio was rebalanced after the close on March 31st, so the difference between the weekly and monthly strategies excludes the very positive last day of the first quarter.  What a difference!  (Of course, that day was included in the previous monthly returns, so all is not lost…).

The news media often says that the market hasn’t had a 10% pullback in quite awhile, but if one is following the monthly or weekly IBD holdings, there is more volatility here than in the more widely followed indexes.

 

As I have been reading reviews of investing and rebalancing into model portfolios, the trading costs of rebalancing weekly or monthly is often discussed.  Going forward, I will list the “in and out” rebalancing costs for each strategy to demonstrate the impact these costs would have on returns.  I will assume a $9.95 cost to sell last week’s or last month’s portfolio, and $9.95 to buy the new weekly or monthly portfolio.  (Imagine the costs of doing this with individual stocks, compared to using Motif).

The Top 25 holdings are listed at at Motif Investing.  (A check as of 3/31/2014 shows that the ability to view all holdings is limited to Motif members and IBD subscribers).

None of the above strategies are a recommendation to buy or sell stocks.  These are model portfolios constructed for entertainment only.

This is the IBD portfolio performance since 2/8/2014.  Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model.  Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month.  It is assumed that trading costs are $9.95 to “buy” a model portfolio, and $9.95 to “sell” a model portfolio.  Thus, each weekly or monthly rebalance out of the previous portfolio and into the new portfolio costs $19.90.  Daily changes in the IBD 50 or stock rankings are not considered.  Changes in IBD’s overall market views are not considered.  Stop loss orders or other market timing strategies are not considered. 

Based on a blog entry from Paladin Money.  See Investors Business Daily for more information on the IBD 50.  See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks.

Sunday, March 09, 2014

Update – The IBD Top 50 Stocks Strategy

Here’s an update on the IBD Top 50 stocks investing strategies vs. $SPY

image For the week, the IBD weekly strategy struggled against the $SPY. This time, maybe Russia gets the blame as QIWI fell sharply with the crisis in Ukraine.  Of course, the ability of the IBD 50 to adjust means that one gets thrown out at the close Friday (IBD had removed it earlier in the week).  So if the crisis ends, the stock could rebound quickly.  But if the crisis lingers and Russian stocks take the hit, Russian and emerging market stocks could continue to get hit.

For the week, there were 29 stocks up and 21 stocks down for the IBD 50.

The total return since 2/8/2014 remains impressive against the SP500.  It’s also interesting to note that the more diversified portfolios have played some catch up to just the handful of stocks in the IBD 5.

What will be interesting to see is how the higher concentration in the high flying stocks performs versus SPY in corrections and sideways moving markets.  Although the make up of the IBD 50 changes, and the top stocks should always be the outperformers. 

Of course, “always” and “never” are words that should be used with caution!

The portfolio is sold at the closing price Friday night, and rebalanced into the make-up of the IBD top 50.

image For the IBD monthly strategy, the strategy is left hanging on to the top 5 stock QIWI through the end of March.  Would you do that if you owned the portfolio?  Or would you sell it for something else?  This is where a mechanical system starts to butt heads with one’s emotions!

It will be interesting to see how the non-adjusted monthly portfolio performs against the weekly portfolio, especially with the month long exposure to stocks getting hit by the Russian crisis.

 

You can view the Top 25 holdings at Motif Investing.

None of the above strategies are a recommendation to buy or sell stocks.  These are model portfolios constructed for entertainment only.

This is the IBD portfolio performance for the week and since 2/8/2014.  Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model.  Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month.  Daily changes in the IBD 50 or stock rankings are not considered.  Changes in IBD’s overall market views are not considered.  Stop loss orders or other market timing strategies are not considered. 

Based on a blog entry from Paladin Money.  See Investors Business Daily for more information on the IBD 50.  See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks.

Sunday, March 02, 2014

Update - The IBD Top 50 Stocks Strategy

Here’s an update on the IBD Top 50 stocks investing strategies vs. $SPY

image For the week, the IBD weekly strategy struggled against the $SPY. This time, “specific stock risk” raised its ugly head as $JAZZ Pharmaceuticals had disappointing earnings and news.  JAZZ does remain above the 50dma, so it will be interesting to see if that provides support.

For the week, there were 29 stocks up and 21 stocks down for the IBD 50.

The total return since 2/8/2014 remains impressive against the SP500.  What will be interesting to see is how the higher concentration in the high flying stocks performs versus SPY in corrections and sideways moving markets.  Although the make up of the IBD 50 changes, and the top stocks should always be the outperformers. 

Of course, “always” and “never” are words that should be used with caution!

The portfolio is sold at the closing price Friday night, and rebalanced into the make-up of the IBD top 50.

imageFor the IBD monthly strategy, the monthly return is equaling the total return, but that is now rebalanced for March.   I expect the differences to show up as the weeks pile up.

Of the top IBD 50 stocks, there were 41 up for the month and only 9 with negative returns.  (Since the 2/8/2014 inception date).

The make-up of the monthly strategy has been updated as of the Friday close, with the latest list of the IBD 50 stocks.

You can view the Top 25 holdings at Motif Investing.

None of the above strategies are a recommendation to buy or sell stocks.  These are model portfolios constructed for entertainment only.

This is the IBD portfolio performance for the week and since 2/8/2014.  Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model.  Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month.  Daily changes in the IBD 50 or stock rankings are not considered.  Changes in IBD’s overall market views are not considered.  Stop loss orders or other market timing strategies are not considered. 

Based on a blog entry from Paladin Money.  See Investors Business Daily for more information on the IBD 50.  See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks.

Saturday, February 22, 2014

Update - The IBD Top 50 Stocks Strategy

Here’s an update on the IBD Top 50 stocks investing strategies vs. $SPY

image For the week, the IBD weekly strategy had another great return. Once again, the concentration in a fewer names at the top of the IBD 50 list outperformed a larger set of names.  The top 5 IBD stocks led the top 10, which led the top 25, which led the top 50.  The SP500 didn’t stand a chance this week.   In a market that is going up everyday, I would expect growth stocks to outperform the SP500 (SPY).

So far, so good.  Is the air getting thin up at the top of the list?

The portfolio is sold at the closing price Friday night, and rebalanced into the make-up of the IBD top 50.

image For the IBD monthly strategy, the monthly return is equaling the total return, as the portfolio will not rebalance until next Friday at the close.  Just two weeks in, there isn’t much difference between the monthly and weekly strategies.  I expect the differences to show up as the weeks pile up.

The make-up of the monthly strategy will remain the same until the last trading day of the month, February 28th.

You can view the Top 25 holdings at Motif Investing.

None of the above strategies are a recommendation to buy or sell stocks.  These are model portfolios constructed for entertainment only.

This is the IBD portfolio performance for the week and since 2/8/2014.  Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model.  Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month.  Daily changes in the IBD 50 or stock rankings are not considered.  Changes in IBD’s overall market views are not considered.  Stop loss orders are not considered. 

Based on a blog entry from Paladin Money.  See Investors Business Daily for more information on the IBD 50.  See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks.

Sunday, February 16, 2014

Update - The IBD Top 50 Stocks Strategy

Here’s an update on the IBD Top 50 stocks investing strategies vs. $SPY

image For the week, the IBD weekly strategy had a great return. The week itself was strong, as the market continues to surge ahead.  It’s interesting that the top 5 stocks outperformed the top 10, which outperformed the top 25, which outperformed the top 50.  In a market that is going up everyday, I would expect growth stocks to outperform the SP500 (SPY).

The portfolio is sold at the closing price Friday night, and rebalanced into the make-up of the IBD top 50.

 

 

image For the month, the IBD monthly strategy had the same return! That’s because it all started on the same day (2/8) as the weekly strategy. 

This should now change as we head into week 2.

The make-up of the monthly strategy will remain the same until the last trading day of the month, February 28th.

You can view the Top 25 holdings at Motif Investing, but interesting to note the UA was the weak performer in 3 of the 4 IBD strategies.  Perhaps it was the drag of the olympic uniforms!

This is the IBD portfolio performance for the week and since 2/8/2014.  Each portfolio begins with $10,000 and then invests an equal amount in the top 5, 10, 25 and 50 IBD stocks at the closing prices on Friday for the weekly model, and at the closing prices on the last trading day of the month for the monthly model.  Since IBD changes the make up of their top stocks daily, this will only rebalance on Fridays or end of month.  Daily changes in the IBD 50 or stock rankings are not considered.  Changes in IBD’s overall market views are not considered.  Stop loss orders are not considered. 

Based on a blog entry from Paladin Money.  See Investors Business Daily for more information on the IBD 50.  See Motif Investing for their IBD Top 25 portfolio, and the ability to construct your own portfolio of stocks. 

Wednesday, December 03, 2008

IBD Follow-Through Day

Tuesday was called a follow-through day by Investor's Business Daily. IBD called today a follow-through day, but I am still cautious because of all the break-out failures lately.  In other words, not every follow-through launches a big market rally. But no market rally has ever started without a follow-through.

Seems like we've had over 5 of those this bear market, and each of them has failed.  Whipsaw City.  Picking the bottom of this bear has been a losers game to date.

Positives?  We seem to be hanging around the 8000 level on the DOW and in the lower-to-mid 800s on the SP500.  Maybe some sort of basing action here. 

I remain long and bullish.  As I mentioned in The Psychology of Cutting Back, I think a lot of what's going on is emotionally driven by the media's gloomy drumbeat.  I see folks with more cash in their wallets now than last year up to this Summer.

(Did someone say Summer?  Summer Glau?)

Oil prices dropping like a stone.  Huge impact to folks out there who drive cars.  It's the stimulus package that keeps on giving.

 

Tuesday, August 12, 2008

Oh, Credit Trouble You Say?

  • The "oil down =stocks up" model took a breather today, but it's back to the "Oh my God the financials are in trouble!" model.  ... the financial sector was hit by more evidence of ongoing credit-related trouble, with the damage partially offset by crude's retreat to $113 a barrel.  "How this story plays out really depends on whether the weakness in financials bleeds out to other sectors in the economy," said Linda Duessel, equity strategist at Federated Investors.
  • This must certainly give the bears an emotional bump.  They were warning yesterday that the last two times the market closed above the 200dma, it was just a head fake and the market crashed. 
  • But boys and girls, IBD says it is NOT a distribution day.
  • Will run the Long-Short model scans later tonight.
  • Microsoft's "blue screen of death" strikes Olympics opening ceremony!  Classic!
  • Consumer's confidence 1-point away from an all-time low!
  • Nancy Pelosi and Michelle Obama to kick off Democratic National Convention.  Pelosi is out trying to sell her Pulitzer (ranked #1929 on Amazon).  And I thought Michelle was in seclusion in a cave somewhere near the Pakistan border.  Where's she been?

Friday, August 08, 2008

8/8/08 Really Big News

  • Yeah, yeah.  China olympics in Beijing.  Thousands of folks dressed up in costumes and banging on drums.  Got it.  Nice LCD screen, by the way.
  • Meanwhile, the big news is the signing of Chad Pennington (not pictured) by the Miami Dolphins.  Pennington was immediately named the starter.
  • The announcement sent the DOW up over 300 points.
  • I don't know what you're thinking, but there has to be a way to trade these NFL QB moves.
  • Heading into the weekend, I remain 100% invested.  We're heading into options week, and it's hard to imagine that could add any volatility to what we've been seeing.
  • The Long-Short system remains on a buy.  Duh, of course.  Nearing the top of the range so it'll be interesting to see how it acts next week.
  • I think a lot of IBD followers are still on the sidelines.  We did have the confirmation day, but we haven't had the kind of leadership one would like to see in a New Bull Market.
  • I think the Fed is on the sidelines until after the election.  Maybe some random comment about inflation or such, but they'll steer clear of The Main Event in November.
  • John Edwards says, well... He did it.  With Rielle Hunter.  Another headlines grabber for awhile.  Aren't we getting a little numb to this stuff by now?
  • Oh, that's Dolphins rookie cheerleader Jennifer!